ADLS1026

ADLS1026 is an investigational therapeutic candidate developed by Zhenao Jinyinhua Pharmaceutical for the treatment of acute ischemic stroke. It is formulated as an injection for intravenous administration. As of early 2025, the drug is in Phase 1 clinical development in China (e.g., trial CTR20252991), where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy adult participants. The developer, Zhenao Jinyinhua Pharmaceutical, is known for its focus on *Lonicera japonica* (Honeysuckle) research, suggesting that ADLS1026 may be a purified botanical extract or a small molecule derived from botanical sources intended to provide neuroprotection or anti-inflammatory effects in the context of ischemic brain injury.